On September 6, 2022 Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, reported that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will participate in two upcoming investor conferences (Press release, Candel Therapeutics, SEP 6, 2022, View Source [SID1234619078]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 17th Annual BioPharma Conference
Format: Investor meetings
Date: Wednesday, September 7
Location: Boston, MA

H.C. Wainwright 24th Annual Global Investment Conference
Format: Webcast company presentation
Date: Monday, September 12
Time: 7:00 AM Eastern Time
Location: Virtual
Webcast link: Available here

A live webcast of the H.C. Wainwright company presentation is available here and can be accessed by visiting the Investors section of Candel Therapeutics’ website at www.ir.candeltx.com and selecting Events and Presentations under the News & Events tab. A replay of the webcast will be archived for up to 90 days following the presentation date.